News | May 10, 2024
Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024
Investing in Malaysia's largest clinic operator to expand the healthcare business
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
With this, for all our USFDA facilities, EIRs are in place
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
